Skip to main content
Premium Trial:

Request an Annual Quote

Exonhit, Cleveland Clinic to Conduct US Clinical Trial of AclarusDx Alzheimer's Test


An institutional review board has approved a pilot clinical trial aimed at evaluating the performance of ExonHit Therapeutics' test for Alzheimer's disease, AclarusDx.

The Paris-based firm said last week that the study, the first AclarusDx trial to be conducted in the US, will be carried out by the Cleveland Clinic and that patient recruitment will begin next month.

ExonHit received a CE-IVD Mark for AclarusDx in March. The Affymetrix-manufactured test is currently offered to select European customers through a partnership with Craigavon, UK-based Almac Diagnostics (BAN 7/5/2011).

ExonHit said it hopes to recruit 160 patients for the trial from three Cleveland Clinic sites: the Lou Ruvo Center for Brain Health in Las Vegas, from which the trial will be coordinated; the main campus in Cleveland; and Lakewood Hospital in Lakewood, Ohio.

Loïc Maurel, president of the management board of Exonhit, said in a statement that the firm's "ultimate goal is to define the clinical utility of AclarusDx to provide primary care physicians with a diagnostic tool that will help them identify patients at high risk of having AD and to prescribe a complete diagnostic workup."

The company has said previously that it hopes to achieve US Food and Drug Administration clearance for the test in 2012.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.